根据可切除NSCLC的病理反应,新辅助剂与外科化疗免疫疗法对比:重建的个体患者数据元分析
Antonio Nuccio1, Fabio Salomone2, Alberto Servetto2
1Università Vita-Salute San Raffaele, Milan, Italy; IRCCS Ospedale San Raffaele, Department of Medical Oncology, Milan, Italy.
Journal of the National Cancer Institute
|April 10, 2025
概括
化学免疫治疗后早期非小细胞肺癌 (NSCLC) 的病理反应显示出明显的生存梯度. 根据病理反应量身定制治疗可能会改善NSCLC患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 翻译医学是一种翻译医学.
- 临床试验 临床试验
背景情况:
- 新辅助化疗免疫疗法显著提升了早期非小细胞肺癌 (NSCLC) 治疗.
- 不同的病理反应水平的预后意义和辅助免疫疗法在术后环境中的作用需要进一步澄清.
研究的目的:
- 评估不同病理反应类别 (pCR,MPR,非MPR) 的预后价值,以新辅助/术后化学免疫疗法治疗早期NSCLC.
- 根据病理反应,比较新辅助剂与外科手术期间的化疗免疫治疗策略的疗效.
主要方法:
- 从已发表的早期NSCLC新辅助剂/外科手术后化学免疫治疗试验中图形重建无事件生存 (EFS) 曲线.
- 根据病理反应分层的生存结果分析,包括新定义的MPR 1-10%子组.
- 在病理反应子组内对新辅助和外科手术期间的策略进行比较.
主要成果:
- 在EFS中观察到显著的预后梯度,完整的病理反应 (pCR) 表明最佳结果,其次是MPR 1-10% (中等) 和无MPR (差).
- 在病理反应子组内,新辅助和外科手术期间的策略之间没有发现EFS的显著差异.
- 在MPR1-10%小组的术后化疗免疫疗法和在没有MPR小组的新辅助化疗免疫疗法中,发现了EFS益处的趋势.
结论:
- 在新辅助化学免疫治疗后的病理反应在早期NSCLC中提供了重要的预后信息.
- 基于病理反应的治疗算法有可能为早期NSCLC患者个性化治疗策略.
更多相关视频
13:37A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
Published on: March 12, 2014
29.9K
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
357
相关概念视频
01:27Tumor Immunotherapy
411
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
411
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
144
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
144
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K